Posted by M.Popov on 12th Nov 2020
Trial size COL17A1 antibodies available in the Antibody Validation Project
Trial size COL17A1 antibodies available in the Antibody Validation Project
Introduction:
Collagen type 17 alpha 1 chain is the protein synthesised by the COL17A1 gene and mediating adhesion of keratinocytes by being a part of the hemidesmosomes. COL17A1 can be localised in the plasma membrane soon to be secreted in the ER and in several tissues, immune cells and regions throughout the human body and mutations in this gene lead to several skin-related diseases and human cancers. We provide a number of trial sized antibodies, which are suitable for COL17A1 research purposes, and to help you make the right decision and find the best suited antibody for you, please find the answers to some of the key topics regarding COL17A1 that we have provided in the links below.
- What is COL17A1?
- Where is COL17A1 found?
- What role does COL17A1 play in disease?
- COL17A1 antibodies in the Antibody Validation project
- Customer reviewed COL17A1 antibodies
- Other COL17A1 antibodies available in the Antibody Validation Project
- Popular COL17A1 antibodies not currently in the Antibody Validation Project
- How does the Antibody Validation Project work?
What is COL17A1?
This gene encodes the alpha chain of type 17 collagen, but unlike most collagens, collagen 17 is a transmembrane protein. Collagen 17 is a structural component of hemidesmosomes, multiprotein complexes at the dermal-epidermal basement membrane zone that mediate adhesion of keratinocytes to the underlying membrane.
Where is COL17A1 found?
COL17A1 is located in the plasma membrane and Golgi apparatus and is believed to be secreted to the extracellular matrix. Furthermore, it is more expressed in placenta, skin and tongue in comparison with other tissues and has enriched human brain region, which is the basal ganglia. Apart from that, inside the immune system it is mainly found in neutrophil.
What role does COL17A1 play in disease?
Mutations in this gene are associated with both generalized atrophic benign and junctional epidermolysis bullosa. in relation, several other disorders are associated with COL17A1, a couple of them being Nail Disorder, Nonsyndromic Congenital, 4 and Epithelial Recurrent Erosion Dystrophy.
COL17A1 antibodies in the Antibody Validation project
St John's Laboratory offers a variety of trial size primary antibodies which target COL17A1 , which are available to try through the Antibody Validation Project. Below we highlight those which have already been reviewed, as well as others which are available to try.
Customer reviewed COL17A1 antibodies
| Model | Name | Host | Clonality | Rating | Application Tested |
|---|---|---|---|---|---|
| STJ92379 | Anti-COL17A1 antibody | Rabbit | Polyclonal | 5 | IHC |
Other COL17A1 antibodies available in the Antibody Validation Project
| Model | Name | Host | Clonality | Recommended Applications |
|---|---|---|---|---|
| STJ98663 | Anti-COL17A1 antibody | Rabbit | Polyclonal | WB,ELISA |
Popular COL17A1 antibodies not currently in the Antibody Validation Project
| Model | Name | Host | Clonality | Recommended Applications |
|---|---|---|---|---|
| STJ112719 | Anti-COL17A1 Antibody | Rabbit | Monoclonal | WB,IHC,IF,IP |
| STJ118789 | Anti-COL17A1 Antibody | Rabbit | Polyclonal | WB |
How does the Antibody Validation Project work?
In order to help our customers with their choice of antibody with low risk, we offer one of the largest ranges of primary antibodies with trial size options available.
The Antibody Validation Project works like this.
1. Order your trial size antibody online.
2. Explore its suitability.
3. Return your results by posting them on the product page.
4. Receive a sample refund.
Find out more here.